Company Overview - Amneal Pharmaceuticals, Inc. is a fully integrated global pharmaceuticals company headquartered in Bridgewater, NJ, with a diverse portfolio of over 270 pharmaceutical products primarily in the United States [3] - The company operates in two main segments: Generics, focusing on complex product categories including injectables and biosimilars, and Specialty, which includes branded pharmaceuticals for central nervous system and endocrine disorders [3] Product Launches - In 2023, Amneal launched 39 new retail and injectable medicines, a significant increase from 26 new launches in 2022 [1] - In the fourth quarter of 2023 alone, the company introduced 13 new products, including 5 injectables such as potassium phosphate vials, tranexamic acid, and esmolol intravenous bags [1] - Key retail products launched in the fourth quarter include spironolactone suspension with 180-day exclusivity, valsartan and hydrochlorothiazide tablets, and icosapent capsules [1] R&D Focus - The R&D portfolio of Amneal prioritizes complex and high-value products aimed at providing better access to affordable medicines for providers and patients [2]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38485 Amneal Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 32-0546926 (State or other jurisdict ...

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET Company Participants Anthony DiMeo - Head-Investor Relations Chirag Patel - Co-Founder & Co-Chief Executive Officer Chintu Patel - Co-Founder & Co-Chief Executive Officer Tasos Konidaris - Chief Financial Officer Joe Renda - Senior Vice President & Chief Commercial Officer-Specialty Harsher Singh - Senior Vice President-Biosciences Conference Call Participants Leszek Sulewski - Truist Balaji Prasad - Barcla ...

Q3 2023 Earnings Call November 7, 2023 Cautionary Statement on Forward Looking Statements Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future, including among other things: discussions of future operations, including internati ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38485 Amneal Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 32-0546926 (State or other jurisdiction o ...

Q2 2023 Earnings Call August 4, 2023 Cautionary Statement on Forward Looking Statements Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future, including among other things: discussions of future operations, including internation ...

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q2 2023 Earnings Conference Call August 4, 2023 8:30 AM ET Company Participants Anthony DiMeo - Head, Investor Relations Chirag Patel - Co-Founder and Co-Chief Executive Officer Chintu Patel - Co-Founder and Co- Co-Chief Executive Officer Tasos Konidaris - Chief Financial Officer Harsher Singh - Head, Biosciences Conference Call Participants Nathan Rich - Goldman Sachs Les Sulewski - Truist David Amsellem - Piper Sandler Operator Hello, everyone and welcome to the Am ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38485 Amneal Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 32-0546926 (State or other jurisdiction ...

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q1 2023 Earnings Conference Call May 5, 2023 8:30 AM ET Company Participants Tony DiMeo - Head-Investor Relations Chirag Patel - President & Co-Chief Executive Officer Chintu Patel - Co-Chief Executive Officer Tasos Konidaris - Executive Vice President, Chief Financial Officer Conference Call Participants Balaji Prasad - Barclays Chris Schott - JPMorgan David Amsellem - Piper Sandler Greg Fraser - Truist Securities Operator Hello, everyone and welcome to the Amneal P ...

amneal We make healthy possible. Q1 2023 Earnings Call May 5, 2023 AMRX LISTED NYSE 2 Cautionary Statement on Forward Looking Statements Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management's intentions, plans, beliefs, expectations or forecasts for the future, including among other things: discus ...